NeuroKaire Featured in OPEN MINDS: NeuroKaire Announces BrightKaire Blood Test To Reduce ‘Trial & Error’ Antidepressant Prescribing

For people living with major depressive disorder, finding the right antidepressant can often mean cycling through medications before identifying one that works. In this Market Watch feature, OPEN MINDS highlights NeuroKaire’s U.S. launch of BrightKaire™, a clinical blood test designed to make antidepressant prescribing more personalized and precise.

The article describes how BrightKaire uses NeuroKaire’s proprietary AI platform to analyze personalized patient data, including genetic background and features of patient-derived neurons, to help predict how an individual may respond to different antidepressants. The report also provides insight into potential adverse events, giving clinical teams information that may support faster, more accurate treatment decisions.

OPEN MINDS’ coverage underscores the growing role of technology-enabled precision psychiatry in mental health care and NeuroKaire’s mission to reduce the uncertainty patients and providers face when selecting depression treatments.

👉 Read the full article

‍